High dose intravenous glucocorticoid pulse (i.v. GCS) therapy is a proven approach in patients with active, moderate to severe Graves' orbitopathy (GO) and dysthyroid optic neuropathy (DON). In moderate to severe GO, the European Group on Graves' Orbitopathy (EUGOGO) recommends a 12-week course of intravenous methylprednisolone (i.v. MP) pulse therapy with a cumulative dose of 4.5 g. The response rate of i.v. GCS treatment is significantly higher than oral glucocorticoid (oral GCS) therapy and is associated with fewer adverse events. However, a major concern was raised because of reports of fatal side effects which may be associated with this therapy, especially when single and cumulative doses of methylprednisolone (MP) are higher than recommended. The prevalence and severity of adverse effects during treatment have not been fully described. The aim of this review was to summarise the frequency of major adverse effects of i.v. GCS compared to oral GCS and attempt to propose some practical suggestions as to how to monitor and prevent the development of side effects. 
Introduction
High dose intravenous glucocorticoid pulse (i.v. GCS) therapy is a highly effective immunosuppressive treatment used in various inflammatory and autoimmune diseases. Despite the introduction of novel therapies (for example rituximab) [1] , intravenous methylprednisolone pulse therapy (i.v. MP) is still considered to be the standard treatment in patients with active, moderate to severe Graves' orbitopathy (GO) and dysthyroid optic neuropathy (DON) [2] . This therapy has been proven to be more effective compared to high dose oral glucocorticoid (oral GCS) therapy and has a lower recurrence rate [3] [4] [5] [6] [7] [8] [9] . Moreover, i.v. MP treatment is associated with fewer 'classical' adverse effects known as exogenous Cushing's syndrome, such as weight gain, hypertension, and 'Cushingoid' features [3, 10] . All these advantages have been extensively described in Prevalence of major side effects during high dose pulse i.v.
GCS treatment
The correct analysis of side effects during i.v. GCS treatment in GO is limited by: (i) a small number of prospective studies; (ii) differences in treatment schedules and daily and cumulative doses of i.v. GCS; and (iii) the fact that not all studies have reported data concerning detailed adverse events. In our study, we first analysed the prevalence of major side effects in 23 randomised and non-randomised prospective trials published between 1983 and 2013 (402 patients treated with i.v. GCS and 358 treated with oral prednisone (details in Fig. 1 ). Then we described the most severe and fatal adverse effects which have been published in retrospective studies, survey studies and case reports. Finally, some examples of adverse effects after i.v. GCS in other diseases were described.
In general, the prevalence of major adverse effects in i.v. GCS treated patients was lower than in the oral GCS group (8.21% vs. 15.08% p = 0.004; RR: 0.54 [95% CI: 0.35-0.84]) (Fig. 1 ). Higher cumulative doses (> 8 g methylprednisolone (MP)/course) are associated with greater toxicity [10, 14, 15] .
Cardiovascular system

Hypertension
The prevalence of hypertension in patients treated with i.v. MP for GO was significantly lower than in patients receiving oral GCS (1.24% vs. 7.82% respectively; RR: 0.19 [95% CI: 0.07-0.47]). Hypertension associated with i.v. GCS therapy may be mild and may resolve spontaneously without additional treatment. However, some cases of severe hypertension in normotensive patients treated with i.v. MP for GO have been reported [16, 17] . In one of them, severe hypertension was followed by myocardial infarction [17] , and in another by acute heart failure [16] .
Cardiac arrhythmias
Cardiac arrhythmias have rarely been reported in patients with GO treated with i.v. MP. However, cardiac arrhythmias have been observed in patients with other diseases after i.v. GCS therapy such as: multiple sclerosis (MS) [18] , lupus-associated hemophagocytic syndrome [19] , rheumatoid arthritis [20] ), Wegener's granulomatosis and juvenile dermatomyositis [21] . Arrhythmias and associated complications can be mild and transient [18, 22] , but in some cases they are life threatening, requiring medical treatment or termination of i.v. GCS therapy. Among them we can distinguish: atrial fibrillation [23] [24] [25] [26] , atrial flutter [27] , junctional rhythm [28] , ventricular tachycardia [29] , supraventricular tachycardia [20] , severe bradycardia [30] [31] [32] ), asystole [28] , cardiovascular collapse [33, 34] , and sudden death [20, 35, 36] . The incidence of significant, life-threatening cardiac arrhythmias after i.v. GCS therapy is higher in smokers, overweight patients, and patients with pre-existing cardiovascular diseases [18] ). They can be observed during a quick i.v. infusion of MP therapy [19] and a few hours after the infusion [20, 21] .
Pulmonary embolism
It is known that patients with endogenous Cushing's syndrome have a higher prevalence of venous thromboembolic events [37] . Although in the analysed studies (both i.v. GCS and oral GCS therapy) incidences The following studies published between 1983 and 2013 were included: prospective randomized studies (n = 18) [4-8, 15, 43, 76, 82-91) , prospective non-randomized studies (n = 5) [77] [78] [79] [80] [81] 
Myocardial infarction and coronary artery disease
Treatment with i.v. GCS may lead to the exacerbation of coronary artery disease (CAD) and acute myocardial infarction (MI) in patients previously diagnosed with CAD [ (42] as well as in undiagnosed [17] or apparently healthy individuals [38] . In the analysed studies, the prevalence of MI in patients treated with i.v. GCS was 0.25% and was not observed after oral GCS therapy. Considering all publications, MI was described in three patients treated with i.v. GCS for GO receiving both high or low doses of MP: one in a prospective randomised trial (one patient/total number of 159 patients in the whole study group) [15] and two case reports [17, 38] . In the first case, of a 66-year-old woman, a cigarette smoker with a previous history of chest pain (two years earlier), MI occurred during very high (1.0 g/day) and everyday scheduled treatment with i.v. MP (cumulative dose -5.0 g) [17] . Coronary angiography revealed complete occlusion of one, and critical obstruction of another, coronary vessel. In the second case, a patient with chronic obstructive pulmonary disease died one week after the 6 th infusion of every-week treatment with MP (dose: 0.25 g/one pulse; cumulative dose -1.5 g) [15] . In the last case, MI appeared in an apparently healthy 75-year-old woman, a former cigarette smoker, during the second cycle, on the 2 nd day of every-five day treatment with 0.5g i.v. MP [cumulative dose for both cycles (in the first cycle 1.0 g/d) -6.0 g] [38] . Her coronary angiography was normal.
Heart failure
Exacerbation of heart failure after i.v. MP therapy for GO is not a common side effect, and so far only one case study has been published [16] . In this case, a 53-year-old previously healthy man developed acute pulmonary oedema. This adverse effect occurred in a hyperthyroid state, two days after radioiodine treatment and therapy with two doses of i.v. MP 1.0 g/day. It could not be ruled out that this exacerbation was a manifestation of thyroid storm.
Cerebrovascular system
In the analysed prospective clinical studies, there was only one case of thrombosis in vena centralis retinae with partial loss of sight after i.v. MP [43] and no other cerebrovascular system (CBV) adverse effects in i.v. GCS as well as in oral GCS treated patients. However, according to a EUGOGO questionnaire survey, five of the 83 (6%) participants reported CBV adverse events [10] , two of which were fatal [10, 38] . In one case, a 24-year-old, smoking, formerly healthy woman died the day after the last infusion of 1.0 g/day of MP for DON (cumulative dose -5.0 g). The postmortem examination revealed thrombosis of the right cerebralmedial artery [38] . In another fatal case, a 45-year-old woman with atrial fibrillation and diabetes mellitus died due to CBV complications 45 days after starting i.v. MP therapy (cumulative dose -11.8 g) [10] . Rare central nervous system complications, such as focal patchy areas on brain MRI, have been reported in patients with systemic lupus erythrematosus treated with i.v. GCS therapy [44, 45] .
Liver damage
Therapy i.v. GCS may cause liver damage, which is a rare side effect but can be irreversible and even fatal [46] [47] [48] [49] [50] . In the analysed clinical studies, after i.v. GCS there were two cases (0.5%) of marked increase of serum aminotranspherases level and none in the oral GCS group. Changes in serum aminotranspherases are associated especially with higher doses of i.v. GCS and become smaller when steroid dosage is lowered [22] . Activation of autoimmune hepatitis can occur even at the beginning of i.v. GCS therapy when the total cumulative dose of GCS is small (Fig. 2) . The prevalence of acute liver damage (ALD) associated with i.v. GCS therapy has been estimated in a group of ~ 800 patients to be 1.0% (eight patients) [48, 49] . In the same study, the prevalence of fatal liver adverse effects was evaluated as ~ 0.3% (three cases of lethal liver complications/800 patients). In all four described lethal cases associated with ALD after i.v. GCS therapy for GO, the cumulative dose of MP was larger than 8.0 g/whole treatment SZKOLENIE PODYPLOMOWE [48, 50] . Liver damage due to i.v. GCS therapy has also been reported in several disorders, including MS [51] [52] [53] .
There are probably three mechanisms leading to ALD: (i) direct, presumably dose-related toxic effect of i.v. GCS on hepatocytes; (ii) induction of virus hepatitis; and (iii) induction of autoimmune hepatitis. Pre-existing viral hepatitis and autoimmune hepatitis are the risk factors of liver damage during the treatment [54, 55] . There is no clear evidence whether liver steatosis should be assessed as an additional risk factor [22, 56] .
Hyperglycaemia and diabetes mellitus
There are only a few studies assessing the influence of i.v. MP for GO on DM or glucose metabolism impairment. In our analysis, 1.67% of patients with GO treated with i.v. MP therapy had exacerbation or diagnosis of new cases of DM (0.84% in oral GCS group) requiring additional treatment.
Psychosis, emotional disorders
Psychiatric disorders from mild euphoria, emotional lability, alteration of behaviour and panic attacks to more serious mood disorders, depression, suicide attempts, psychosis and delirium can occur in patients treated with glucocorticoids (GCS) [57, 58] with and without a previous history of such diseases [59] . In our analysis, we observed four cases (1.24%) of depression and one of psychosis after i.v. MP therapy for GO. However, in patients treated with oral GCS, the prevalence of psychiatric disorders was higher (2.51%).
Infections
GCS are potent immunosuppressive and anti-inflammatory drugs. Infections are common and dangerous adverse effects. In the analysed clinical studies in GO, the prevalence of new infections was 2.74% with i.v. MP. Among them there was one patient with viral pneumonia. The prevalence of this adverse effect in patients treated with oral GCS was slightly higher (3.91%). The relative risk of infections during GCS therapy was estimated in a retrospective analysis of 71 controlled clinical trials to be 1.6 [60] .
Practical suggestions for i.v. MP therapy
What should be done before starting i.v. MP treatment?
The probability of occurrence of adverse effects after i.v. MP therapy can be reduced by the assessment and optimal treatment of all risk factors. In some situations, postponing i.v. GCS therapy is necessary (treatment of the coexisting diseases e.g. angioplasty in CAD, modification of hypertension or DM treatment, therapy of infection, chronic heart failure).
Firstly, a careful medical history should be taken, with an extra focus on cardiovascular or cerebrovascular diseases, peptic ulcers, thromboembolic events, psychiatric disorders, infectious diseases (HBV, HCV, Varicella-Zoster, tuberculosis) or fragility fracture. Secondly, a complete physical examination should be done, including measurement of body weight, blood pressure, signs of infections, cardiac arrhythmias or heart failure.
Based 
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-glaucoma [2, 62, 63] or cataracts [63] [64] [65] ; -urine infection [2] . Moreover, in particular patients, other tests should also be considered before i.v. MP treatment: -psychiatric consultation -in cases of history of psychiatric disorders [66, 67] -dual X-ray absorptiometry (DXA) is recommended at baseline in all patients starting GCS treatment with doses ≥ 5 mg prednisone or its equivalent according to the Polish Recommendations for the Prevention and Treatment of Osteoporosis [68] or any dose according to ACR [69] with an anticipated duration of more than three months. It seems reasonable to consider this procedure also in patients treated with i.v. MP; -gastroscopy -in patients with a positive medical history of peptic ulcers, especially those receiving Non-Steroidal Anti-Inflammatory Drugs (NSAID) [70] [71] [72] ; -tuberculin skin test or interferon gamma release assays (IGRAs) in patients with a history of tuberculosis or with incidental findings on chest radiograph suggestive of tuberculosis [73] ; -ECG or 24 h holter-ECG; -CRP as a marker of infection.
What are the contraindications to MP pulse treatment?
According to the available drug information, contraindications to MP treatment are: hypersensitivity to MP or any component of the formulation [74] ; tuberculosis, bacterial or viral infection without specific treatment, systemic fungal infection, administration of live virus vaccines.
Moreover, i.v. MP therapy should not be given to patients with such contraindications as: -liver dysfunction (4-5-fold increased level of liver enzymes) or recent hepatitis; -cardiovascular morbidity, e.g.: unstable CAD, severe heart failure, severe arrhythmias, uncontrolled hypertension; -uncontrolled diabetes mellitus [3, 11] ; -psychiatric disorders (decisions should be made in all cases concomitantly with psychiatrist); -uncontrolled glaucoma; i.v. MP has been shown to increase intraocular pressure (IOP) [75] and some authors consider glaucoma as a contraindication for i.v. MP. On the other hand, other experts do not consider well controlled and carefully monitored glaucoma as an absolute contraindication, especially if it may be secondary to GO.
What should be monitored during the treatment?
It is advisable to perform a careful clinical examination before each pulse of MP (paying attention to symptoms/ signs of CAD, infections, psychiatric disorders, blood pressure). The basic diagnostic set before each pulse is not clearly defined. Some authors recommend measurement of liver enzymes (every 1-2 weeks) and performing ECG (before each MP pulse) [11] . In our opinion, it may be reasonable to perform the following lab tests before each MP pulse: serum potassium (especially in patients on diuretics), glucose concentration (especially in patients with DM), AST and ALT activity and urine analysis [92] .
To prevent iatrogenic glaucomatous nerve damage, ophthalmological examination, including the intraocular pressure measurement, should be regularly performed.
It is important to remember that a slow rate of i.v. MP infusion (minimum 60-90 min) should be used in all patients [10] to avoid serious cardiac arrhythmias. Whether in all cases it is safe to perform i.v. MP treatment on an out-patient basis remains an open question.
The occurrence of adverse effects may require a modification of current therapy (e.g. in hypertension, DM), and in the majority of such cases i.v. MP can be continued. Slightly elevated liver enzymes require careful observation and are not a definitive contraindication for further treatment. In cases of relevant liver dysfunction (i.e. a greater than fourfold -fivefold upper normal limit of liver enzymes), i.v. MP therapy should be stopped [3, 11] . Recognition of infection is an indication for postponing i.v. MP therapy and a directed treatment is necessary. In rare cases (e.g. MI, pulmonary embolism, stroke, ALD), i.v. MP should be stopped and other treatment modalities for GO should be considered.
It is also very important to pay special attention to smoking cessation, because it is known that there is a strong correlation between smoking and the response to GCS treatment [93] .
Conclusions
Therapy i.v. MP for GO is highly efficient, mostly safe, and associated with a lower prevalence of major adverse effects than oral GCS treatment. However, this therapy should be conducted in specialised centres which have enough experience to properly judge the benefits and potential risks of i.v. MP therapy.
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Polish version
Wstęp
Terapia z zastosowaniem dużych dawek glikokortykosteroidów w postaci dożylnych pulsów (i.v. GCS, intravenous glucocorticoid pulse) jest skutecznym leczeniem stosowanym w chorobach autoimmunologicznych i zapalnych. Pomimo rozwoju nowych metod leczenia (rituksimab) [1] , terapia dożylnymi pulsami metyloprednizolonu (i.v. MP, intravenous methylprednisolone) pozostaje leczeniem z wyboru u chorych z aktywną, umiarkowaną do ciężkiej orbitopatią Gravesa (GO, Graves' orbitopathy) i neuropatią nerwów wzrokowych w przebiegu GO (DON, dysthyroid optic neuropathy) [2] . Wyniki badań wskazują na jej większą skuteczność i niższy odsetek nawrotów w porównaniu z glikokortykosteroidami doustnymi (oral GCS, oral glucocorticoid) [3] [4] [5] [6] [7] [8] [9] . Ponadto leczenie i.v. MP jest lepiej tolerowane i rzadziej związane z występowaniem "klasycznych" objawów egzogennego zespołu Cushinga, takich jak: wzrost masy ciała, nadciśnienie tętnicze, cushingoidalna sylwetka ciała [3, 10] . Częstość występowania poważnych działań niepożądanych w trakcie leczenia i.v. GCS
